Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BUB1 | O43683 | 3/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.35 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.35 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.35 |
| ▸ | MMP13 | P45452 | 1/20 | 0.34 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.33 |
| ▸ | AAK1 | Q2M2I8 | 1/20 | 0.32 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.31 |
| ▸ | ADRA1B | P35368 | 1/20 | 0.31 |
| ▸ | BRPF1 | P55201 | 1/20 | 0.30 |
| ▸ | AVPR1A | P37288 | 1/20 | 0.30 |
| ▸ | MMP2 | P08253 | 1/20 | 0.30 |
| ▸ | MMP9 | P14780 | 1/20 | 0.30 |
| ▸ | ADAM17 | P78536 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8764748 | 0.81 | MAPK1 (0.42) | MAPK1SCN9AEPHX2BRPF1AVPR1A | |
| SCHEMBL16718559 | 0.68 | EPHX2 (0.43) | BUB1SCN9AMMP13EPHX2 | |
| SCHEMBL22518274 | 0.68 | EPHX2 (0.43) | BUB1SCN9AMMP13EPHX2 | |
| SCHEMBL15413892 | 0.67 | PYGL (0.46) | SCN9A | |
| SCHEMBL15414007 | 0.67 | PYGL (0.46) | SCN9A | |
| SCHEMBL15413893 | 0.67 | PYGL (0.46) | SCN9A | |
| SCHEMBL27132340 | 0.66 | MTOR (0.49) | BUB1L3MBTL1MMP13AAK1 | |
| SCHEMBL16989834 | 0.66 | XIAP (0.37) | SCN9A | |
| SCHEMBL22539103 | 0.66 | XIAP (0.43) | SCN9A | |
| SCHEMBL15564956 | 0.64 | RIPK1 (0.49) | SCN9AEPHX2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3071562-B1 | TETRAHYDRO-BENZODIAZEPINONES | HOFFMANN LA ROCHE (CH) | 2020-10-14 | — | — | EP | disclosed |
| US-10053431-B2 | Tetrahydro-benzodiazepinones | HOFFMANN-LA ROCHE INC. (US) | 2018-08-21 | — | — | US | disclosed |
| EP-3071562-A1 | TETRAHYDRO-BENZODIAZEPINONES | F. Hoffmann-La Roche AG (CH) | 2016-09-28 | — | — | EP | disclosed |
| US-20160272596-A1 | TETRAHYDRO-BENZODIAZEPINONES | HOFFMANN-LA ROCHE INC. | 2016-09-22 | — | — | US | disclosed |
| WO-2015071393-A1 | TETRAHYDRO-BENZODIAZEPINONES | F. HOFFMANN-LA ROCHE AG (CH) | 2015-05-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10053431-B2 | Tetrahydro-benzodiazepinones | GABBR1, TPH1, GABBR2 | BUB1 992/4885MAPK1 4626/4885L3MBTL1 2441/4885 |
| US-20160272596-A1 | TETRAHYDRO-BENZODIAZEPINONES | GABBR1, TPH1, GABBR2 | BUB1 992/4885MAPK1 4626/4885L3MBTL1 2441/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.